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Mephedrone use is 
increasing in London
The UK Psychoactive Substances Act 
2016, which received Royal Assent on 
Jan 28, 2016,1 aims to eradicate the 
market in new psychoactive 
substances, but we question how 
effective the banning of these drugs 
might be. 
The synthetic stimulant mephedrone 
was one of the first, new psychoactive 
substances available, emerging around 
2007.2 It was subsequently classified as 
a Class B substance in the UK under the 
Misuse of Drugs Act in April, 2010, and 
is also controlled in several other 
countries worldwide.
Anecdotal evidence suggests that 
mephedrone is rarely used in the USA 
or Europe as a whole. However, there 
has been a strong increase in the 
number of people presenting for 
mephedrone treatment in England,3 
and mephedrone is regularly detected 
in post-mortem samples analysed at 
the Toxicology Unit, Imperial College 
London, from coroners’ jurisdictions 
across London and southeast England.
The number of deaths in which 
mephedrone was detected in 2015 
(n=34, 1·5% of total cases received) 
has increased since 2014 (n=22, 
1·0%). The number of deaths 
associated with mephedrone is 
comparable to the number of deaths 
in which methylenedioxymethyl-
amphetamine (MDMA), an 
established recreational drug, was 
detected (n=28, 1·2% of total cases in 
2015 and n=25, 1·1% in 2014).
These mephedrone-associated deaths 
occurred in three distinct user groups. 
Recreational drug users who take the 
drug in combination with alcohol or 
other typical recreational drugs, such 
as cocaine, amfetamine, or MDMA; 
intravenous drug users combining 
mephedrone with heroin; and men who 
have sex with men (MSM) who combine 
the drug with γ-hydroxybutyrate and 
metamfetamine. In 2015, all 
mephedrone-associated deaths 
identified by the Toxicology Unit were 
in men, 68% of whom were MSM.
The authors of the European 
Monitoring Centre for Drugs and Drug 
Addiction report2 on the risk 
assessment of mephedrone in 2011 
concluded that the decision to control 
the drug has the potential to reduce 
the availability and usage, but could 
also create an illicit market. Our data 
suggests that, despite being a 
controlled substance, mephedrone 
has remained popular on the London 
drug scene, and has become an 
established drug of choice in a diverse 
population of drug users. 
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